Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms
NCT05956600 · University of California, Los Angeles · NA · withdrawn · last registry update 2024-06-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Action of PI. Loss of sponsor” | – | Registry record, University of California, Los Angeles |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR1F within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-31Also stopped (terminated): Messoud Ashina, MD, Almotriptan 12.5 Mg Oral Tablet + Ubrogepant 50Mg Tab (NCT05214001)
- 2025-04-11Results posted on the registry: University of California, San Diego, amisulpride + bromocriptine (NCT04128683)
- 2024-10-21Results posted on the registry: Technical University of Munich, Olanzapine or amisulpride (NCT01029769)
- 2024-09-19Results posted on the registry: All India Institute of Medical Sciences, Bhubaneswar, Amisulpride + Olanzapine-Fluoxetine Combination (NCT04876521)
- 2024-09-05Phase 3 first posted: Benaroya Research Institute, Amisulpride IV Prevention + Amisulpride IV Treatment (NCT06585540)
- 2024-02-01Results posted on the registry: Eli Lilly and Company, Lasmiditan + Dabigatran Etexilate (NCT04749914)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision